Regulus Therapeutics shares are trading lower after the company announced results in the Phase 1b Study for ADPKD treatment. The stock initially traded higher, but it has since reversed.
Portfolio Pulse from Benzinga Newsdesk
Regulus Therapeutics shares are trading lower after the company announced results in the Phase 1b Study for ADPKD treatment. The stock initially traded higher, but it has since reversed.
June 24, 2024 | 3:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Regulus Therapeutics shares are trading lower following the announcement of results from their Phase 1b study for ADPKD treatment. The stock initially saw an uptick but has since reversed direction.
The announcement of the Phase 1b study results for ADPKD treatment initially caused an uptick in Regulus Therapeutics' stock price, but the reversal indicates that the market may have found the results less favorable upon closer inspection. This has led to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100